Chinanews.com Yinchuan, August 20th, title: China-Arab States Expo builds a platform for Chinese medicine to "go out to sea" by express train
China News Service reporter Li Peishan
Since last year, the "health packs" received by Chinese students abroad have made many foreigners "jumped". In this "health pack" containing masks, disinfectant wipes and other anti-epidemic materials and anti-epidemic drugs, Lianhua Qingwen Capsules has become a well-deserved one. "Internet celebrities".
At the Fifth China-Arab Expo "One Belt One Road" Investment Promotion Conference held on the 19th, Sun Xuefei, general manager of the International Trade Center of Shijiazhuang Yiling Pharmaceutical Co., Ltd. also brought good news: the drug is expected to be approved for import in Morocco To help it fight the new crown epidemic.
"Unexpectedly, my family will be able to buy Lianhua Qingwen in the future." Ning Baoyun, a Moroccan expert from Ningxia Wisdom Palace Cultural Industry Group Co., Ltd., has been working in China for a long time. She witnessed the epidemic situation last year and this year. The role of medicine in the fight against the epidemic is also eagerly hoped that China and its own countries will get rid of the epidemic as soon as possible.
Lianhua Qingwen Capsule is a proprietary Chinese medicine developed by Chinese pharmaceutical companies that uses both cold and heat.
A clinical study of new coronary pneumonia published in "Plant Medicine" showed that after 14 days of treatment for Lianhua Qingwen, the recovery rate reached 91.5%.
At present, the "function and indication" item in the drug's instructions has been approved and added "in the conventional treatment of new coronavirus pneumonia, it can be used for mild and common fever, cough, and fatigue".
Sun Xuefei told reporters that as the pace of internationalization of Chinese medicine continues to accelerate, in countries along the “Belt and Road”, Chinese medicine is an important weapon to curb the spread of the virus.
Under the advocacy of experts and officials, traditional Chinese medicine has become more and more popular, becoming a permanent home for Chinese families, and selling well overseas.
Taking Lianhua Qingwen Capsules as an example, countries along the “Belt and Road” such as Iraq, Nepal and Thailand have received medicines worth more than 3.5 million yuan.
At the same time, the drug has obtained registration approvals or import licenses in nearly 30 countries and regions.
The drug has also been approved for new coronary pneumonia indications in Kuwait and Mongolia, and has been allowed to enter the designated hospitals for new coronary pneumonia in Indonesia, Thailand, Cambodia and other countries.
"Not long ago, Lianhua Qingwen was selected as a home treatment program for mild patients with new coronary pneumonia in Cambodia. This is also the first time that Chinese medicine has entered a foreign country's new coronary pneumonia diagnosis and treatment program." Recognition continues to rise.
During the China-Arab States Expo, Sun Xuefei also continued to provide advice and suggestions for Chinese medicine to expand its overseas "circle of friends".
He said that it is very important to promote the theory of Chinese medicine and develop academic cooperation.
“The epidemic has enabled overseas experts and people to gradually understand and accept Chinese medicine, creating an opportunity for the development of Chinese medicine culture to the world. Many overseas Chinese medicine hospitals."
Of course, bottlenecks such as the difficulty of transnational registration and the need to expand overseas markets also hinder the process of internationalization of Chinese medicine.
Sun Xuefei believes that the application of evidence-based medicine can make Chinese medicine more standardized, and make the evaluation of the effectiveness and safety of Chinese medicine diagnosis and treatment methods more suitable for the global discourse system.
"We have completed more than 20 evidence-based medicine research projects related to proprietary Chinese medicines, and are still studying more valuable scientific evidence for global sharing." (End)